« Return to News | CROs/Service Providers

Molecular Profiles invests $14.3 million in new facility in Nottingham

Tuesday, March 6, 2012 06:00 AM

Molecular Profiles, a contract research and manufacturing organization, has begun construction of a new manufacturing facility in Nottingham, U.K.

The $14.3 million investment will allow Molecular Profiles to expand its current manufacturing capabilities. The U.K. government allocated a regional growth fund grant of $2.5 million. 

The new GMP facility, planned to open in late 2012, will provide an additional 30,000 square feet of space consisting of six new GMP suites, several laboratories and a clinical packing suite. The facility will enable flexibility of use and the manufacture of highly potent compounds up to OEB 4 level. It is also designed to handle a range of dosage forms including solids, liquids, semi-solids and inhaled products. The expanded capability allows Molecular Profiles to comprehensively cover phase I and II clinical trial requirements with manufacturing batch scale of up to 30kg.

The investment will enable expansion across all Molecular Profiles’ services, including formulation development, polymorph and salt selection, analytical services, materials characterization and clinical trial manufacturing.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.